BTK and B-cell chronic lymphocytic leukemia: In a cohort of 13 zanubrutinib-treated patients, ten patients with progressive CLL had C481 mutations and seven patients had BTK L528W mutations, suggesting that acquired L528W mutations may play a role in zanubrutinib resistance in addition to C481 mutations [22].